Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: A literature review

Eunhee S. Yi, Jin Haeng Chung, Kimary Kulig, Keith M. Kerr

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Anaplastic lymphoma kinase (ALK) encodes a receptor tyrosine kinase, and ALK gene rearrangement (ALK) is implicated in the oncogenesis of non-small cell lung carcinomas (NSCLCs), especially adenocarcinomas. The ALK inhibitor crizotinib was approved in August 2011 by the US Food and Drug Administration (FDA) for treating late-stage NSCLCs that are ALK, with a companion fluorescent in situ hybridization (FISH) test using the Vysis ALK Break Apart FISH Probe Kit. This review covers pertinent issues in ALK testing, including approaches to select target patients for the test, pros and cons of different detection methods, and mechanisms as well as monitoring of acquired crizotinib resistance in ALK NSCLCs.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalMolecular Diagnosis and Therapy
Volume16
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Gene Rearrangement
Non-Small Cell Lung Carcinoma
Therapeutics
Fluorescence In Situ Hybridization
anaplastic lymphoma kinase
Receptor Protein-Tyrosine Kinases
United States Food and Drug Administration
Carcinogenesis
Adenocarcinoma

Keywords

  • Adenocarcinoma
  • Anaplastic-lymphoma- kinase-targets
  • Anaplastic-lymphoma-kinase-inhibitors
  • Crizotinib
  • Drug-resistance
  • Non-small-cell-lung-cancer

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Medicine(all)
  • Pharmacology

Cite this

Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy : A literature review. / Yi, Eunhee S.; Chung, Jin Haeng; Kulig, Kimary; Kerr, Keith M.

In: Molecular Diagnosis and Therapy, Vol. 16, No. 3, 2012, p. 143-150.

Research output: Contribution to journalArticle

@article{e15bf016f2484f1a9eaa618fcb47c6d4,
title = "Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: A literature review",
abstract = "Anaplastic lymphoma kinase (ALK) encodes a receptor tyrosine kinase, and ALK gene rearrangement (ALK) is implicated in the oncogenesis of non-small cell lung carcinomas (NSCLCs), especially adenocarcinomas. The ALK inhibitor crizotinib was approved in August 2011 by the US Food and Drug Administration (FDA) for treating late-stage NSCLCs that are ALK, with a companion fluorescent in situ hybridization (FISH) test using the Vysis ALK Break Apart FISH Probe Kit. This review covers pertinent issues in ALK testing, including approaches to select target patients for the test, pros and cons of different detection methods, and mechanisms as well as monitoring of acquired crizotinib resistance in ALK NSCLCs.",
keywords = "Adenocarcinoma, Anaplastic-lymphoma- kinase-targets, Anaplastic-lymphoma-kinase-inhibitors, Crizotinib, Drug-resistance, Non-small-cell-lung-cancer",
author = "Yi, {Eunhee S.} and Chung, {Jin Haeng} and Kimary Kulig and Kerr, {Keith M.}",
year = "2012",
doi = "10.2165/11632830-000000000-00000",
language = "English (US)",
volume = "16",
pages = "143--150",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy

T2 - A literature review

AU - Yi, Eunhee S.

AU - Chung, Jin Haeng

AU - Kulig, Kimary

AU - Kerr, Keith M.

PY - 2012

Y1 - 2012

N2 - Anaplastic lymphoma kinase (ALK) encodes a receptor tyrosine kinase, and ALK gene rearrangement (ALK) is implicated in the oncogenesis of non-small cell lung carcinomas (NSCLCs), especially adenocarcinomas. The ALK inhibitor crizotinib was approved in August 2011 by the US Food and Drug Administration (FDA) for treating late-stage NSCLCs that are ALK, with a companion fluorescent in situ hybridization (FISH) test using the Vysis ALK Break Apart FISH Probe Kit. This review covers pertinent issues in ALK testing, including approaches to select target patients for the test, pros and cons of different detection methods, and mechanisms as well as monitoring of acquired crizotinib resistance in ALK NSCLCs.

AB - Anaplastic lymphoma kinase (ALK) encodes a receptor tyrosine kinase, and ALK gene rearrangement (ALK) is implicated in the oncogenesis of non-small cell lung carcinomas (NSCLCs), especially adenocarcinomas. The ALK inhibitor crizotinib was approved in August 2011 by the US Food and Drug Administration (FDA) for treating late-stage NSCLCs that are ALK, with a companion fluorescent in situ hybridization (FISH) test using the Vysis ALK Break Apart FISH Probe Kit. This review covers pertinent issues in ALK testing, including approaches to select target patients for the test, pros and cons of different detection methods, and mechanisms as well as monitoring of acquired crizotinib resistance in ALK NSCLCs.

KW - Adenocarcinoma

KW - Anaplastic-lymphoma- kinase-targets

KW - Anaplastic-lymphoma-kinase-inhibitors

KW - Crizotinib

KW - Drug-resistance

KW - Non-small-cell-lung-cancer

UR - http://www.scopus.com/inward/record.url?scp=84861680382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861680382&partnerID=8YFLogxK

U2 - 10.2165/11632830-000000000-00000

DO - 10.2165/11632830-000000000-00000

M3 - Article

C2 - 22506598

AN - SCOPUS:84861680382

VL - 16

SP - 143

EP - 150

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 3

ER -